Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

BACKGROUND: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer overexpressing HER2/neu in about 30% of cases. Trastuzumab, a humanized monoclonal antibody targeting Her2/Neu, in combination with carboplatin/paclitaxel, is considered the preferred regimen for the treatment...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Gynecol Oncol Rep
Main Authors: Pelligra, Silvia, Buza, Natalia, Hui, Pei, Bellone, Stefania, Zeybek, Burak, Ratner, Elena, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2020
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049633/
https://ncbi.nlm.nih.gov/pubmed/32140533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2020.100554
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki